Loading company…
MBD uses 3D cell culture technology to support cancer drug research, screening and treatment development.
Founded in 2015 and based in Suwon-si, South Korea, MBD develops 3D cell culture platforms for drug efficacy and toxicity research, including work on anti-cancer drugs. Its products include Cellvitro, ASFA Spotter and ASFA Scanner. In August 2025, the company raised KRW 16.5 billion in Series C funding from new and returning investors.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in